Advertisement

Topics

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015

07:44 EDT 11 Aug 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-29. This 372-page report is available in PDF from $2000.

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015’, provides an overview of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Table of Contents
Table of Contents 2
Introduction 6
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Overview 7
Therapeutics Development 8
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Development by Companies 10
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics under Investigation by Universities/Institutes 17
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Products Glance 21
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Development by Companies 25
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Products under Investigation by Universities/Institutes 32
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Companies Involved in Therapeutics Development 35
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Therapeutics Assessment 108
Drug Profiles 119
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Recent Pipeline Updates 292
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Dormant Projects 340
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Discontinued Products 347
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Product Development Milestones 348
Appendix 355

For more information open Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015.

SKU: GMDHC6680IDB

Original Article: Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

MRSA (methicillin-resistant Staphylococcus aureus)
MRSA (methicillin-resistant Staphylococcus aureus) is a family of bacteria with resistance to one or more major antibiotics. There are currently 17 different strains of MRSA. Two particular strains, EMRSA15 and EMRSA16  account for 96% of MRSA blood...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...